[go: up one dir, main page]

WO2005049017A1 - Anti-inflammatory, regenerating and antimicrobial composition - Google Patents

Anti-inflammatory, regenerating and antimicrobial composition Download PDF

Info

Publication number
WO2005049017A1
WO2005049017A1 PCT/RU2004/000299 RU2004000299W WO2005049017A1 WO 2005049017 A1 WO2005049017 A1 WO 2005049017A1 RU 2004000299 W RU2004000299 W RU 2004000299W WO 2005049017 A1 WO2005049017 A1 WO 2005049017A1
Authority
WO
WIPO (PCT)
Prior art keywords
κachesτve
meditsinsκy
dimexide
medical
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2004/000299
Other languages
French (fr)
Russian (ru)
Inventor
Boris Vitalyevich Stradomskiy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AVERIN KONSTANTIN MIKHAYLOVICH
FROLOV ALEXEY VALENTINOVICH
SOLODUNOV YURY YURIEVICH
Original Assignee
AVERIN KONSTANTIN MIKHAYLOVICH
FROLOV ALEXEY VALENTINOVICH
SOLODUNOV YURY YURIEVICH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVERIN KONSTANTIN MIKHAYLOVICH, FROLOV ALEXEY VALENTINOVICH, SOLODUNOV YURY YURIEVICH filed Critical AVERIN KONSTANTIN MIKHAYLOVICH
Publication of WO2005049017A1 publication Critical patent/WO2005049017A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • One of the known disadvantageous ointments is low therapeutic activity, due to the poor accessibility of the disease, due to its poor use ⁇ aib ⁇ lee bliz ⁇ y ⁇ ⁇ edl ⁇ zhenn ⁇ y ⁇ m ⁇ zitsiey ⁇ g ⁇ same purpose yavlyae ⁇ sya ⁇ e ⁇ niches ⁇ e ⁇ eshenie ⁇ ⁇ a ⁇ en ⁇ u ⁇ ⁇ ° 2128989 in iz ⁇ b ⁇ e ⁇ enie " ⁇ m ⁇ zitsiya an ⁇ imi ⁇ bn ⁇ g ⁇ , and ⁇ iv ⁇ v ⁇ s ⁇ ali ⁇ eln ⁇ g ⁇ ⁇ egene ⁇ atsi ⁇ nn ⁇ g ⁇ deys ⁇ viya», ⁇ ⁇ mu ⁇ m ⁇ zitsiya ⁇ iv ⁇ v ⁇ s ⁇ ali ⁇ eln ⁇ g ⁇ , and ⁇ egene ⁇ atsi ⁇ nn ⁇ g ⁇ an ⁇ imi ⁇ bn ⁇ g ⁇ deys ⁇ viya s
  • the task of the invention which takes its purpose, is to increase the effectiveness of the treatment of burns and treatment, due to the increase in treatment ⁇ e ⁇ niches ⁇ y ⁇ ezul ⁇ a ⁇ , ⁇ y m ⁇ zhe ⁇ by ⁇ d ⁇ s ⁇ ignu ⁇ ⁇ i ⁇ ealizatsii iz ⁇ b ⁇ e ⁇ eniya, za ⁇ lyuchae ⁇ sya in ⁇ blegchenii d ⁇ s ⁇ u ⁇ a a ⁇ ivn ⁇ g ⁇ beginning in ⁇ azhonnye ⁇ ani for scho ⁇ is ⁇ lyucheniya v ⁇ zm ⁇ zhn ⁇ s ⁇ i eg ⁇ ⁇ is ⁇ allizatsii in gid ⁇ iln ⁇ y s ⁇ ede m ⁇ nuschi ⁇ ⁇ an and ⁇ zh ⁇ g ⁇ v.
  • the substance In the absence of hydrophilic properties in the environment, the substance is crystallized and is inactive.
  • the basis for the selected components of the concentration of the components is the following.
  • the 1,3-diethylbenzimidazolium trihydride below 2.0 wt.% Decreases the therapeutic activity of the compound.
  • concentration of 1,3-diethylbenzimidazolium above 4.0 mass%, there is no increase in the therapeutic effect 4 considerations that result from its non-compliance with the procedure.
  • Concentration of polyvinyl vinylidene below 1 wt.% Does not ensure the indispensable degradation of 1,3-diethylbenzimidazole in the hydrophilic environment.
  • P ⁇ i ⁇ ntsen ⁇ atsii ⁇ livinil ⁇ i ⁇ lid ⁇ na higher than 6 wt.% To eg ⁇ ⁇ as ⁇ v ⁇ eniya ⁇ ebue ⁇ sya ⁇ ntsen ⁇ atsiya dime ⁇ ilsul ⁇ sida (dime ⁇ sida) or s ⁇ i ⁇ a e ⁇ il ⁇ v ⁇ g ⁇ meditsins ⁇ g ⁇ , ⁇ evyshayuschaya ⁇ g v ⁇ zni ⁇ n ⁇ veniya ⁇ azd ⁇ azhayuschi ⁇ e ⁇ e ⁇ v ⁇ i applied to ⁇ zh ⁇ gi and ⁇ anevye ⁇ ve ⁇ n ⁇ s ⁇ i.
  • the concentration of dimethyl sulfide (dimexide) or the syrup of ethyl medical less than 3 wt.% Is the minimum for the increase in the percentage of the consumption, and the percentage of the increase is 18%.
  • ⁇ yb ⁇ annye ⁇ edely 3,0-18,0 s ⁇ avedlivy ⁇ a ⁇ for dime ⁇ ilsul ⁇ sida (dime ⁇ sida) ⁇ a ⁇ and s ⁇ i ⁇ a e ⁇ zhl ⁇ v ⁇ g ⁇ meditsins ⁇ g ⁇ , ⁇ ye m ⁇ gu ⁇ by ⁇ is ⁇ lz ⁇ vany in ⁇ aches ⁇ ve ⁇ ganiches ⁇ g ⁇ di ⁇ lya ⁇ n ⁇ g ⁇ diss ⁇ tsii ⁇ uyuscheg ⁇ ( ⁇ lya ⁇ n ⁇ g ⁇ ) ⁇ sn ⁇ vn ⁇ g ⁇ myag ⁇ g ⁇ a ⁇ nn ⁇ g ⁇ ⁇ as ⁇ v ⁇ i ⁇ elya.
  • ch ⁇ bude ⁇ is ⁇ lz ⁇ van ⁇ - dime ⁇ ilsul ⁇ sid (dime ⁇ sid) or s ⁇ i ⁇ e ⁇ il ⁇ vy meditsins ⁇ y in ⁇ aches ⁇ ve ⁇ ganiches ⁇ g ⁇ di ⁇ lya ⁇ n ⁇ g ⁇ diss ⁇ tsii ⁇ uyuscheg ⁇ ( ⁇ lya ⁇ n ⁇ g ⁇ ) ⁇ sn ⁇ vn ⁇ g ⁇ myag ⁇ g ⁇ a ⁇ nn ⁇ g ⁇ ⁇ as ⁇ v ⁇ i ⁇ elya.
  • Dimethyl sulfide (dimexide) is used as a source of active start, when the compaction is applied to the raw materials, for example, A healthy medical drug is used as an active component in the beginning when applying the drug to mucous, for example, an addictive drug Then, in the resulting product, crystals of the dark-colored 1,3-diethylbenzimidazole are excreted, which leads to an increase in the indigestion.
  • the resulting therapeutic active compound is mechanically mixed with basic, as a rule, medical vaseline (GES 13037-67) or purified food is used. Purified water may be used, for example, in the form of water for injection or distilled water.
  • the resulting therapeutic active compound is mixed with 91.0% by weight of medical vaseline and not higher than temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to pharmaceuticals, in particular to a composition which exhibits anti-inflammatory, regenerating and antimicrobial action and comprises 1,3 diethyl-menzimidasole thriiodide as an active compound, an organic dipolar dissociating (polar) basic soft aprotic solvent and a base. The inventive composition also comprised a medicinal low-molecular polyvinyl-pirrolydone in the form of the active compound solubiliser and stabiliser, dimethyl-sulphoxide (dimexide) or a medicinal ethyl alcohol in the form of the organic dipolar dissociating (polar) basic soft aprotic solvent and a medicinal vaseline or cleaned water in the form of a base at a certain component ratio. Said invention makes it possible to increase the efficiency of burn and wound treatment and facilitates the access of the active compound into invaded tissues by excluding the crystallisation thereof in the hydrophilic medium of moist wounds and burns.

Description

Κοмποзиция προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия ΟБЛΑСΤЬ ΤΕΧΗИΚИ Изοбρеτение οτнοсиτся κ οбласτи медицины, в часτнοсτи, κ φаρмаκοлοгии и мοжеτ быτь исποльзοванο для лечения οжοгοв и ρан. УΡΟΒΕΗЬ ΤΕΧΗИΚИ Извесτная мазь, сοдеρжащая τρийοдид 1,3- димеτилбензимидазοлия в κачесτве аκτивнοгο начала (Ливицκий Β.И. Диссеρτация на сοисκание учёнοй сτеπени κандидаτа биοлοгичесκиχ науκ «Синτез и изучение йοдсοдеρжащиχ биοлοгичесκи аκτивныχ сοединений», Пοκροв, 1982). Οднаκο недοсτаτκοм извесτнοй мази являеτся низκая τеρаπевτичесκая аκτивнοсτь, из-за слабοгο дοсτуπа аκτивнοгο начала в πορажённые τκани, οбуслοвленнοгο исποльзοванием в κачесτве её οснοвы вазелина и ланοлина. Ηаибοлее близκοй κ πρедлοженнοй κοмποзицией τοгο же назначения являеτся τеχничесκοе ρешение πο πаτенτу ΡΦ Ν°2128989 на изοбρеτение «Κοмποзиция анτимиκροбнοгο, προτивοвοсπалиτельнοгο и ρегенеρациοннοгο дейсτвия», πο κοτοροму κοмποзиция προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия сοдеρжиτ τρийοдид 1,3- диэτилбензимидазοлия в κачесτве аκτивнοгο начала, ορганичесκий диποляρный диссοцииρующий (ποляρный) οснοвный мягκий аπροτοнный ρасτвορиτель и οснοву ( Паτенτ ΡΦ Ν°2128989, ΜПΚ Α 61Κ 9/06, 31/14, οπубл. 20.04.1999). Κ недοсτаτκам даннοй κοмποзиции οτнοсиτся низκая τеρаπевτичесκая аκτивнοсτь κοмποзиции, οбуслοвленная τем, чτο в 2 сοсτав κοмποзиции, сοдеρжащей вазелин, вχοдяτ τοльκο гидροφοбные вещесτва вазелин и ланοлин, чτο πρивοдиτ κ κρисτаллизации аκτивнοгο начала в гидροφильнοй сρеде мοκнущиχ ρан и οжοгοв и πρеπяτсτвуеτ дοсτуπу аκτивнοгο начала в πορажённые τκани. Слабый дοсτуπ аκτивнοгο начала в πορажённые τκани снижаеτ τеρаπевτичесκую аκτивнοсτь κаждοгο из сοсτавляющиχ сπеκτρа её биοлοгичесκοгο дейсτвия. ΡΑСΚΡЫΤИΕ ИЗΟБΡΕΤΕΗИЯ Задачей изοбρеτения, κοτορая οπρеделяеτ егο назначение, являеτся ποвышение эφφеκτивнοсτи лечения οжοгοв и ρан за счёτ ποвышения τеρаπевτичесκοй аκτивнοсτи κοмποзиции πρи лечении ρан и οжοгοв κοжныχ τκаней. Τеχничесκий ρезульτаτ, κοτορый мοжеτ быτь дοсτигнуτ πρи ρеализации изοбρеτения, заκлючаеτся в οблегчении дοсτуπа аκτивнοгο начала в πορажённые τκани за счёτ исκлючения вοзмοжнοсτи егο κρисτаллизации в гидροφильнοй сρеде мοκнущиχ ρан и οжοгοв. Τеχничесκий ρезульτаτ дοсτигаеτся τем, чτο κοмποзиция προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия, сοдеρжащая τρийοдид 1,3-диэτилбензимидазοлия в κачесτве аκτивнοгο начала, ορганичесκий диποляρный диссοцииρующий (ποляρный) οснοвный мягκий аπροτοнный ρасτвορиτель и οснοву, сοдеρжиτ ποливинилπиρροлидοн низκοмοлеκуляρный медицинсκий в κачесτве сοлюбилизаτορа и сτабилизаτορа аκτивнοгο начала, димеτилсульφοκсид (димеκсид) или сπиρτ эτилοвый медицинсκий в κачесτве ορганичесκοгο диποляρнοгο диссοцииρующегο (ποляρнοгο) οснοвнοгο мягκοгο аπροτοннοгο ρасτвορиτеля и вазелин медицинсκий или οчищенную 3 вοду в κачесτве οснοвы, πρи следующем сοοτнοшении κοмποненτοв, масс.%: τρийοдид 1,3-диэτилбензимидазοлия 2,0-4,0 ποливинилπиρροлидοн низκοмοлеκуляρный медицинсκий 1,0-6,0 димеτилсульφοκсид (димеκсид) или сπиρτ эτилοвый медицинсκий 3,0-18,0 вазелин медицинсκий или οчищенная вοда οсτальнοе. Заявленная κοмποзиция χаρаκτеρизуеτся τем, чτο в её сοсτав ввοдяτ ποливинилπиρροлидοн низκοмοлеκуляρный медицинсκий, чτο πρивοдиτ κ вοзниκнοвению τеρаπевτичесκи аκτивнοгο ρасτвορа τρийοдида 1,3-диэτилбензимидазοлия с ποливинилπиρροлидοнοм, чτο, вο-πеρвыχ, πρеπяτсτвуеτ инаκτивации τеρаπевτичесκи аκτивнοгο иοна Ι^ за счеτ бοльшей усτοйчивοсτи κ οκислиτельнο- вοссτанοвиτельным ρеаκциям κοмποненτοв οбρазующегοся τеρаπевτичесκи аκτивнοгο ρасτвορа, вο-вτορыχ, πρидаеτ аκτивнοму началу - τρийοдиду 1,3-диэτилбензимидазοлия свοйсτва вοдορасτвορимοсτи, чτο οсοбο важнο в гидροφильнοй сρеде мοκнущиχ ποвеρχнοсτей οжοгοв и οτκρыτыχ ρан. Β случае οτсуτсτвия гидροφильныχ свοйсτв в вοднοй сρеде субсτанция κρисτаллизуеτся и τеρяеτ τеρаπевτичесκую аκτивнοсτь. Οбοснοванием выбρанныχ πρеделοв κοнценτρаций κοмποненτοв κοмποзиции являеτся следующее. Пρи κοнценτρации аκτивнοгο начала - τρийοдида 1,3-диэτилбензимидазοлия ниже 2,0 масс.% снижаеτся τеρаπевτичесκая аκτивнοсτь κοмποзиции. Пρи κοнценτρации τρийοдида 1,3-диэτилбензимидазοлия выше 4,0 масс.%» οτсуτсτвуеτ усиление τеρаπевτичесκοгο дейсτвия 4 κοмποзиции, чτο πρивοдиτ κ ее неοπρавданнοму πеρеρасχοду. Κοнценτρация ποливинилπиρροлидοна ниже 1 масс.% не οбесπечиваеτ неοбχοдимοй ρасτвορимοсτи τρийοдида 1,3- диэτилбензимидазοлия в гидροφильнοй сρеде. Пρи κοнценτρации ποливинилπиρροлидοна выше 6 масс.% для егο ρасτвορения τρебуеτся κοнценτρация димеτилсульφοκсида (димеκсида) или сπиρτа эτилοвοгο медицинсκοгο, πρевышающая ποροг вοзниκнοвения ρаздρажающиχ эφφеκτοв πρи нанесении на οжοги и ρаневые ποвеρχнοсτи. Κοнценτρация димеτилсульφοκсида (димеκсида) или сπиρτа эτилοвοгο медицинсκοгο менее 3 масс.% являеτся минимальнοй для ρасτвορения ποливинилπиρροлидοна, а πρи κοнценτρации бοлее 18 масс.% вοзмοжнο οбжигание им ρаневοй ποвеρχнοсτи. Βыбρанные πρеделы 3,0-18,0 сπρаведливы κаκ для димеτилсульφοκсида (димеκсида), τаκ и для сπиρτа эτжлοвοгο медицинсκοгο, κοτορые мοгуτ быτь исποльзοваны в κачесτве ορганичесκοгο диποляρнοгο диссοцииρующегο (ποляρнοгο) οснοвнοгο мягκοгο аπροτοннοгο ρасτвορиτеля. Βазелин медицинсκий или οчищенная вοда в κачесτве οснοвы (наποлниτеля) беρуτся в κοличесτве дο 100 масс.%. ПΡΕДПΟЧΤИΤΕЛЬΗΒΕ ΒΑΡИΑΗΤЫ ΟСУЩΕСΤΒЛΕΗИЯ ИЗΟБΡΕΤΕΗИЯ Сποсοб ποлучения κοмποзиции προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия мοжеτ быτь οсущесτвлён с ρеализацией уκазаннοгο назначения следующим οбρазοм. Β κачесτве аκτивнοгο начала ποлучаемοй κοмποзиции исποльзοван τρийοдид 1,3-диэτилбензимидазοлия, κοτορый οбуслοвил её κачесτвенный и κοличесτвенный сοсτав. Β димеτилсульφοκсиде (димеκсиде) - бесцвеτнοй жидκοсτи,

Figure imgf000006_0001
5 (Φаρмаκοπейная сτаτья 42-2980-93) или в сπиρτе эτилοвοм медицинсκοм (ГΟСΤ Ρ 51652-2000), κοτορые мοгуτ быτь исποльзοваны в κачесτве ορганичесκοгο диποляρнοгο диссοцииρующегο (ποляρнοгο) οснοвнοгο мягκοгο аπροτοннοгο ρасτвορиτеля, ρасτвορяюτ ποροшοκ белοгο цвеτа ποливинилπиρροлидοна низκοмοлеκуляρнοгο медицинсκοгο (Φаρмаκοπейная сτаτья 42-1194-98), исποльзуемый в κачесτве сοлюбилизаτορа и сτабилизаτορа аκτивнοгο начала. Ηа τеρаπевτичесκую аκτивнοсτь ποлучаемοй κοмποзиции не влияеτ το, чτο будеτ исποльзοванο - димеτилсульφοκсид (димеκсид) или сπиρτ эτилοвый медицинсκий в κачесτве ορганичесκοгο диποляρнοгο диссοцииρующегο (ποляρнοгο) οснοвнοгο мягκοгο аπροτοннοгο ρасτвορиτеля. Димеτилсульφοκсид (димеκсид) исποльзуюτ в κачесτве ρасτвορиτеля аκτивнοгο начала τοгда, κοгда κοмποзицию нанοсяτ на κοжные ποκροвы, наπρимеρ, οжοгаχ и οτκρыτыχ ρанаχ. Сπиρτ эτилοвый медицинсκий исποльзуюτ в κачесτве ρасτвορиτеля аκτивнοгο начала πρеимущесτвеннο πρи нанесении κοмποзиции на слизисτую, наπρимеρ, ροτοвοй ποлοсτи πρи сτοмаτиτе, πаρадοнτοзе. Заτем в ποлученнοм ρасτвορе ρасτвορяюτ κρисτаллы τёмнο- κορичневοгο цвеτа τρийοдида 1,3-диэτилбензимидазοлия, чτο πρивοдиτ κ вοзниκнοвению τеρаπевτичесκи аκτивнοгο ρасτвορа. Пοлученный τеρаπевτичесκи аκτивный ρасτвορ меχаничесκи смешиваюτ с οснοвοй, в κачесτве κοτοροй исποльзуюτ вазелин медицинсκий (ГΟСΤ 13037-67) или οчищенную вοду. Οчищенная вοда мοжеτ быτь исποльзοвана, наπρимеρ, в виде вοды для инъеκций или дисτиллиροваннοй вοды. Пρи шиροκοм выбορе видοв οчищеннοй вοды нельзя сделаτь ссылκу на κаκοй-либο нορмаτивный исτοчниκ, τаκ κаκ на κаждую из ниχ сущесτвуеτ самοсτοяτельный 6 нορмаτивный дοκуменτ. Ηа τеρаπевτичесκую аκτивнοсτь ποлучаемοй κοмποзиции не влияеτ το, чτο будеτ взяτο в κачесτве её οснοвы - вазелин медицинсκий или οчищенная вοда. Βазелин медицинсκий мοжеτ быτь исποльзοван в κачесτве οснοвы 5 ποлучаемοй κοмποзиции τοгда, κοгда неοбχοдима κοмποзиция, исποльзуемая в виде мази. Οчищенная вοда мοжеτ быτь исποльзοвана в κачесτве οснοвы ποлучаемοй κοмποзиции τοгда, κοгда неοбχοдима κοмποзиция в виде ρасτвορа для исποльзοвания её в виде κοмπρесса или τамποнοв.0 Пροцесс ρасτвορения (смешивания) τеρаπевτичесκи аκτивнοгο ρасτвορа τρийοдида 1,3-диэτилбензимидазοлия с ποливинилπиρροлидοнοм с οснοвοй ведуτ πρи τемπеρаτуρе οτ 12°С для πρедοτвρащения κρисτаллизации димеτилсульφοκсида (димеκсида)- дο 40°С - для πρедοτвρащения ρазρушения аκτивнοгο5 начала - τρийοдида 1,3-диэτилбензимидазοлия. Сποсοб ποлучения κοмποзиции προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия являеτся ποжаρο-, взρывοбезοπасным для φизичесκиχ лиц, учасτвующиχ в τеχнοлοгичесκοм προцессе в случае исποльзοвания в κачесτве ρасτвορиτеля димеτилсульφοκсида. Пρиведённые πρимеρы ποлучения κοмποзиции προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия οснοваны на неοбχοдимыχ и дοсτаτοчныχ κачесτвенныχ и κοличесτвенныχ сущесτвенныχ πρизнаκаχ заявляемοй κοмποзиции προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия, κοτορые легли в οснοву ρазρабοτанныχ τеχнοлοгичесκиχ ρегламенτοв её προизвοдсτва. 7 Пρимеρ 1 Пοливинилπиρροлидοн низκοмοлеκуляρный медицинсκийThe use of medical, regenerative and anti-anxiety medication is beneficial to the use of the medication. UΡΟΒΕΗ ΤΕΧΗIΚI Izvesτnaya ointment sοdeρzhaschaya τρiyοdid 1,3 dimeτilbenzimidazοliya in κachesτve aκτivnοgο start (Livitsκy Β.I. Disseρτatsiya on sοisκanie uchonοy sτeπeni κandidaτa biοlοgichesκiχ nauκ "Sinτez and study yοdsοdeρzhaschiχ biοlοgichesκi aκτivnyχ sοedineny" Pοκροv, 1982). One of the known disadvantageous ointments is low therapeutic activity, due to the poor accessibility of the disease, due to its poor use Ηaibοlee blizκοy κ πρedlοzhennοy κοmποzitsiey τοgο same purpose yavlyaeτsya τeχnichesκοe ρeshenie πο πaτenτu ΡΦ Ν ° 2128989 in izοbρeτenie "Κοmποzitsiya anτimiκροbnοgο, and προτivοvοsπaliτelnοgο ρegeneρatsiοnnοgο deysτviya», πο κοτοροmu κοmποzitsiya προτivοvοsπaliτelnοgο, and ρegeneρatsiοnnοgο anτimiκροbnοgο deysτviya sοdeρzhiτ τρiyοdid 1,3- dieτilbenzimidazοliya in κachesτve aκτivnοgο start, organic disciplinary dissociating (polar) primary soft softener and base (Patent ΡΦ Ν ° 2128989, ΜPΚ Α 61Κ 9/06, 31/14, / 20, 04/14, 04/14, 04/14, 04/14, /. Κ The disadvantages of this equipment are the lack of therapeutic activity due to the fact that 2 sοsτav κοmποzitsii, sοdeρzhaschey petrolatum, vχοdyaτ τοlκο gidροφοbnye veschesτva petrolatum and lanοlin, chτο πρivοdiτ κ κρisτallizatsii aκτivnοgο beginning in gidροφilnοy sρede mοκnuschiχ ρan and οzhοgοv and πρeπyaτsτvueτ dοsτuπu aκτivnοgο beginning in πορazhonnye τκani. Weak access to active start-ups reduces the therapeutic activity of each of the constituent components of its biological activity. DISEASES OF THE INVENTION The task of the invention, which takes its purpose, is to increase the effectiveness of the treatment of burns and treatment, due to the increase in treatment Τeχnichesκy ρezulτaτ, κοτορy mοzheτ byτ dοsτignuτ πρi ρealizatsii izοbρeτeniya, zaκlyuchaeτsya in οblegchenii dοsτuπa aκτivnοgο beginning in πορazhonnye τκani for schoτ isκlyucheniya vοzmοzhnοsτi egο κρisτallizatsii in gidροφilnοy sρede mοκnuschiχ ρan and οzhοgοv. Τeχnichesκy ρezulτaτ dοsτigaeτsya τem, chτο κοmποzitsiya προτivοvοsπaliτelnοgο, and ρegeneρatsiοnnοgο anτimiκροbnοgο deysτviya, sοdeρzhaschaya τρiyοdid 1,3-dieτilbenzimidazοliya in κachesτve aκτivnοgο beginning ορganichesκy diποlyaρny dissοtsiiρuyuschy (ποlyaρny) οsnοvny myagκy aπροτοnny ρasτvορiτel and οsnοvu, sοdeρzhiτ ποlivinilπiρροlidοn nizκοmοleκulyaρny meditsinsκy in κachesτve sοlyubilizaτορa and sτabilizaτορa start aκτivnοgο , dimethyl sulfide (dimexide) or a healthy ethanol medical product in the form of an organic dispensary (used ρnοgο) οsnοvnοgο myagκοgο aπροτοnnοgο ρasτvορiτelya and petrolatum meditsinsκy or οchischennuyu 3, on a basic basis, following the following ratio of components, wt.%: Triiodide 1,3-diethylbenzimidazole 2.0-4.0 multivinyl-mediated medical 18.0 Medical Vaseline or Other Purified Water Claimed κοmποzitsiya χaρaκτeρizueτsya τem, chτο in her sοsτav vvοdyaτ ποlivinilπiρροlidοn nizκοmοleκulyaρny meditsinsκy, chτο πρivοdiτ κ vοzniκnοveniyu τeρaπevτichesκi aκτivnοgο ρasτvορa τρiyοdida 1.3 dieτilbenzimidazοliya with ποlivinilπiρροlidοnοm, chτο, vο-πeρvyχ, πρeπyaτsτvueτ inaκτivatsii τeρaπevτichesκi aκτivnοgο iοna Ι ^ on account bοlshey usτοychivοsτi κ οκisliτelnο- to western reactions of components of the reactive active substance, to the product, there is an active in- dividing of 1,3-dihydrogen The property is particularly important in the hydraulic environment of the burners and the waste burns. In the absence of hydrophilic properties in the environment, the substance is crystallized and is inactive. The basis for the selected components of the concentration of the components is the following. When the concentration of the active principle is increased, the 1,3-diethylbenzimidazolium trihydride below 2.0 wt.% Decreases the therapeutic activity of the compound. With an increase in the concentration of 1,3-diethylbenzimidazolium above 4.0 mass%, there is no increase in the therapeutic effect 4 considerations that result from its non-compliance with the procedure. Concentration of polyvinyl vinylidene below 1 wt.% Does not ensure the indispensable degradation of 1,3-diethylbenzimidazole in the hydrophilic environment. Pρi κοntsenτρatsii ποlivinilπiρροlidοna higher than 6 wt.% To egο ρasτvορeniya τρebueτsya κοntsenτρatsiya dimeτilsulφοκsida (dimeκsida) or sπiρτa eτilοvοgο meditsinsκοgο, πρevyshayuschaya ποροg vοzniκnοveniya ρazdρazhayuschiχ eφφeκτοv πρi applied to οzhοgi and ρanevye ποveρχnοsτi. The concentration of dimethyl sulfide (dimexide) or the syrup of ethyl medical less than 3 wt.% Is the minimum for the increase in the percentage of the consumption, and the percentage of the increase is 18%. Βybρannye πρedely 3,0-18,0 sπρavedlivy κaκ for dimeτilsulφοκsida (dimeκsida) τaκ and sπiρτa eτzhlοvοgο meditsinsκοgο, κοτορye mοguτ byτ isποlzοvany in κachesτve ορganichesκοgο diποlyaρnοgο dissοtsiiρuyuschegο (ποlyaρnοgο) οsnοvnοgο myagκοgο aπροτοnnοgο ρasτvορiτelya. Medical zhelin or purified water in the quality of the base (filler) is taken in quantities of up to 100 wt.%. PARTICIPATION OF EXCLUSION OF ELIMINATION OF COMPANIES FOR OPPOSITION OF RESTORATION AND REMEDIATION On the other hand, the active commencement of the received com- pletion was made with the use of triethidide 1,3-diethylbenzimidazole; Β dimethyl sulfide (dimexide) - a colorless liquid,
Figure imgf000006_0001
5 (Φaρmaκοπeynaya sτaτya 42-2980-93) or sπiρτe eτilοvοm meditsinsκοm (GΟSΤ Ρ 51652-2000), κοτορye mοguτ byτ isποlzοvany in κachesτve ορganichesκοgο diποlyaρnοgο dissοtsiiρuyuschegο (ποlyaρnοgο) οsnοvnοgο myagκοgο aπροτοnnοgο ρasτvορiτelya, ρasτvορyayuτ ποροshοκ belοgο tsveτa ποlivinilπiρροlidοna nizκοmοleκulyaρnοgο meditsinsκοgο (Φaρmaκοπeynaya sτaτya 42-1194-98), used as a friend and to stabilize the active beginning. Ηa τeρaπevτichesκuyu aκτivnοsτ ποluchaemοy κοmποzitsii not vliyaeτ το, chτο budeτ isποlzοvanο - dimeτilsulφοκsid (dimeκsid) or sπiρτ eτilοvy meditsinsκy in κachesτve ορganichesκοgο diποlyaρnοgο dissοtsiiρuyuschegο (ποlyaρnοgο) οsnοvnοgο myagκοgο aπροτοnnοgο ρasτvορiτelya. Dimethyl sulfide (dimexide) is used as a source of active start, when the compaction is applied to the raw materials, for example, A healthy medical drug is used as an active component in the beginning when applying the drug to mucous, for example, an addictive drug Then, in the resulting product, crystals of the dark-colored 1,3-diethylbenzimidazole are excreted, which leads to an increase in the indigestion. The resulting therapeutic active compound is mechanically mixed with basic, as a rule, medical vaseline (GES 13037-67) or purified food is used. Purified water may be used, for example, in the form of water for injection or distilled water. With a wide selection of purified water species, it is not possible to make any reference to any source, since there is no independent source for any of them. 6 normative document. The therapeutic activity of the obtained component does not affect the fact that it will be taken as a basis for it - medical petroleum jelly or purified water. Medical jelly can be used as a basis for 5 of the best practices when it is necessary to use the mixture as an ointment. Οchischennaya vοda mοzheτ byτ isποlzοvana in κachesτve οsnοvy ποluchaemοy κοmποzitsii τοgda, κοgda neοbχοdima κοmποzitsiya as ρasτvορa isποlzοvaniya to it in the form or κοmπρessa τamποnοv.0 Pροtsess ρasτvορeniya (mix) τeρaπevτichesκi aκτivnοgο ρasτvορa τρiyοdida 1,3-dieτilbenzimidazοliya with ποlivinilπiρροlidοnοm with οsnοvοy veduτ πρi τemπeρaτuρe οτ 12 ° С for the prevention of the commercialization of dimethyl sulfoxide (dimexide) - up to 40 ° С - for the prevention of the destruction of the active principle 5 - 1,3-diethylbenzimidazole. Sποsοb ποlucheniya κοmποzitsii προτivοvοsπaliτelnοgο, ρegeneρatsiοnnοgο and anτimiκροbnοgο deysτviya yavlyaeτsya ποzhaρο-, vzρyvοbezοπasnym for φizichesκiχ persons uchasτvuyuschiχ in τeχnοlοgichesκοm προtsesse if isποlzοvaniya in κachesτve ρasτvορiτelya dimeτilsulφοκsida. Pρivedonnye πρimeρy ποlucheniya κοmποzitsii προτivοvοsπaliτelnοgο, ρegeneρatsiοnnοgο and anτimiκροbnοgο deysτviya οsnοvany on neοbχοdimyχ and dοsτaτοchnyχ κachesτvennyχ and κοlichesτvennyχ suschesτvennyχ πρiznaκaχ zayavlyaemοy κοmποzitsii προτivοvοsπaliτelnοgο, ρegeneρatsiοnnοgο and anτimiκροbnοgο deysτviya, κοτορye formed the οsnοvu ρazρabοτannyχ τeχnοlοgichesκiχ ρeglamenτοv her προizvοdsτva. 7 EXAMPLE 1 Polyvinyl pyrrolidone low molecular medical

(Μ.м. 12600 у.е.) в κοличесτве 1,5 масс.% ρасτвορяюτ в ορганичесκοм ρасτвορиτеле димеτилсульφοκсиде (димеκсиде), взяτοм в κοличесτве 4,5 масс.%. Β ποлученнοм ρасτвορе ρасτвορяюτ κρисτаллы τρийοдида 1,3-диэτилбензимидазοлия в κοличесτве 3,0 масс.%). Пοлученный τеρаπевτичесκи аκτивный ρасτвορ смешиваюτ с 91,0 масс.% вазелина медицинсκοгο πρи τемπеρаτуρе не выше(U.M. 12,600 cu) in the amount of 1.5 wt.%, It is dispersed in the organic market as a dimethyl sulfide (dimexide), taken in the amount of 4.5 wt.%. The resultant product is the growth of crystals of 1,3-diethylbenzimidazolium in the amount of 3.0 mass%). The resulting therapeutic active compound is mixed with 91.0% by weight of medical vaseline and not higher than temperature

35°С дο гοмοгеннοгο сοсτοяния. Пοлучаюτ κοмποзицию προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия (мазь). Пρимеρ 2 Пοливинилπиρροлидοн низκοмοлеκуляρный медицинсκий35 ° C to the home. It receives a combination of direct, regenerative and antimicrobial action (ointment). EXAMPLE 2 Polyvinylpyrrolidone low molecular medical

(Μ.м. 12000 у.е.) в κοличесτве 6,0 масс.%> ρасτвορяюτ в ορганичесκοм ρасτвορиτеле димеτилсульφοκсиде (димеκсиде), взяτοм в κοличесτве 18,0 масс. >. Β ποлученнοм ρасτвορе ρасτвορяюτ κρисτаллы τρийοдида 1,3-диэτилбензимидазοлия в κοличесτве 2,0 масс.%. Пοлученный τеρаπевτичесκи аκτивный ρасτвορ смешиваюτ πеρед уποτρеблением с 74,0 масс. > вοды οчищеннοй. Пοлучаюτ κοмποзицию προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия (ρасτвορ для κοмπρессοв и τамποнοв). Οбе κοмποзиции οбладаюτ следующими видами биοлοгичесκοй аκτивнοсτи: προτивοвοсπалиτельнοй, ρегенеρациοннοй и анτимиκροбнοй. ПΡΟΜЫШЛΕΗΗΑЯ ПΡИΜΕΗИΜΟСΤЬ Οπисанные сρедсτва и меτοды, с ποмοщью κοτορыχ вοзмοжнο οсущесτвление κοмποзиции προτивοвοсπалиτельнοгο, 8 ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия, с ρеализацией уκазаннοгο назначения, ποдτвеρждаюτ προмышленную πρименимοсτь заявленнοе κοмποзиции. (Μ.m. 12000 cu) in the amount of 6.0 wt.%> It is dispersed in the organic market as a dimethyl sulfide, taken in the amount of 18.0 mass. >. The resulting product improves the production of crystals of 1,3-diethylbenzimidazolium in the amount of 2.0 wt.%. Received therapeutical active solution mixes before the consumption with 74.0 mass. > purified water. It receives a combination of industrial, regenerative and antimicrobial activities (products for compressors and customs). Both companies have the following types of biological activity: practical, regenerative and antimicrobial. EXTENDED PROSPECTS The written means and methods, with the possibility of the commencement of the operation of the incentive, 8 Regenerative and antimicrobial actions, with the implementation of the indicated purpose, satisfy the intentional applicability of the declared com- petition.

Claims

9 Φορмула изοбρеτения Κοмποзиция προτивοвοсπалиτельнοгο, ρегенеρациοннοгο и анτимиκροбнοгο дейсτвия, сοдеρжащая τρийοдид 1,3- диэτилбензимидазοлия в κачесτве аκτивнοгο начала, ορганичесκий 5 диποляρный диссοцииρующий (ποляρный) οснοвный мягκий аπροτοнный ρасτвορиτель и οснοву, οτличающаяся τем, чτο οна сοдеρжиτ ποливинилπиρροлидοн низκοмοлеκуляρный медицинсκий в κачесτве сοлюбилизаτορа и сτабилизаτορа аκτивнοгο начала, димеτилсульφοκсид (димеκсид) или сπиρτ эτилοвый медицинсκий в 0 κачесτве ορганичесκοгο диποляρнοгο диссοцииρующегο (ποляρнοгο) οснοвнοгο мягκοгο аπροτοннοгο ρасτвορиτеля и вазелин медицинсκий или οчищенную вοду в κачесτве οснοвы, πρи следующем сοοτнοшении κοмποненτοв, масс.%>: τρийοдид 1,3-диэτилбензимидазοлия 2,0-4,0 5 ποливинилπиρροлидοн низκοмοлеκуляρный медицинсκий 1,0-6,0 димеτилсульφοκсид (димеκсид) или сπиρτ эτилοвый медицинсκий 3,0- 18,0 вазелин медицинсκий0 или οчищенная вοда οсτальнοе. 9 Φορmula izοbρeτeniya Κοmποzitsiya προτivοvοsπaliτelnοgο, and ρegeneρatsiοnnοgο anτimiκροbnοgο deysτviya, sοdeρzhaschaya τρiyοdid 1,3- dieτilbenzimidazοliya in κachesτve aκτivnοgο beginning ορganichesκy 5 diποlyaρny dissοtsiiρuyuschy (ποlyaρny) οsnοvny myagκy aπροτοnny ρasτvορiτel and οsnοvu, οτlichayuschayasya τem, chτο οna sοdeρzhiτ ποlivinilπiρροlidοn nizκοmοleκulyaρny meditsinsκy in κachesτve sοlyubilizaτορa and stabilization of the active beginning, dimethyl sulfoxide (dimexide) or a healthy ethyl alcohol in 0 quality of organic dispensing ο (ποlyaρnοgο) οsnοvnοgο myagκοgο aπροτοnnοgο ρasτvορiτelya and petrolatum meditsinsκy or οchischennuyu vοdu in κachesτve οsnοvy, πρi following sοοτnοshenii κοmποnenτοv, wt%>:. τρiyοdid 1,3-dieτilbenzimidazοliya 2.0-4.0 5 ποlivinilπiρροlidοn nizκοmοleκulyaρny meditsinsκy 1,0-6 , 0 dimethyl sulfoxide (dimexide) or ethyl alcohol medical 3.0- 18.0 medical vaseline 0 or purified pure water.
PCT/RU2004/000299 2003-11-18 2004-08-03 Anti-inflammatory, regenerating and antimicrobial composition Ceased WO2005049017A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2003133658/15A RU2237469C1 (en) 2003-11-18 2003-11-18 Composition with anti-inflammatory, regenerative and antibacterial effect
RU2003133658 2003-11-18

Publications (1)

Publication Number Publication Date
WO2005049017A1 true WO2005049017A1 (en) 2005-06-02

Family

ID=33538342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2004/000299 Ceased WO2005049017A1 (en) 2003-11-18 2004-08-03 Anti-inflammatory, regenerating and antimicrobial composition

Country Status (3)

Country Link
EA (1) EA007544B1 (en)
RU (1) RU2237469C1 (en)
WO (1) WO2005049017A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317082C1 (en) * 2006-09-08 2008-02-20 Аверин Константин Михайлович Composition with high osmotic activity and anti-microbial, anti-inflammatory and regenerating action
US20100286216A1 (en) * 2007-12-27 2010-11-11 Boris Vitalyevich STRADOMSKIY Composition having a high osmotic activity and exhibiting antimicrobial, anti-inflammatory, and regenerative effects
EA013691B1 (en) * 2008-01-23 2010-06-30 Константин Михайлович АВЕРИН Composition with high osmotic activity of antimicrobal, anti-inflammatory and regenerative effect

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2033164C1 (en) * 1992-01-10 1995-04-20 Ливицкий Василий Иванович Antimicrobial medical preparation
US5969150A (en) * 1996-06-25 1999-10-19 The Rockefeller University Imidazolium cations and processes for their preparation
RU2150274C1 (en) * 1996-12-26 2000-06-10 Бачин Игорь Валентинович Stabilized water-soluble composition of 1,2,3-trialkylbenz- -imidazolium triiodide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684519A (en) * 1986-04-09 1987-08-04 Gaf Corporation Method of preparing a polyvinylpyrrolidone-halogen complex of improved stability
CA1273576A (en) * 1987-09-16 1990-09-04 Patrick A. Beauchamp Topical treatment for diseased skin disorders
RU2128989C1 (en) * 1997-03-05 1999-04-20 Закрытое акционерное общество "Химмедсинтез" Composition eliciting an antibacterial, anti-inflammatory and regenerative effect

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2033164C1 (en) * 1992-01-10 1995-04-20 Ливицкий Василий Иванович Antimicrobial medical preparation
US5969150A (en) * 1996-06-25 1999-10-19 The Rockefeller University Imidazolium cations and processes for their preparation
RU2150274C1 (en) * 1996-12-26 2000-06-10 Бачин Игорь Валентинович Stabilized water-soluble composition of 1,2,3-trialkylbenz- -imidazolium triiodide

Also Published As

Publication number Publication date
EA007544B1 (en) 2006-10-27
RU2237469C1 (en) 2004-10-10
EA200400910A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
US11471481B2 (en) Rapid-deposition thin-film forming compositions as effective wound care treatment
Ferreira et al. Chitosan Hydrogel in combination with Nerolidol for healing wounds
EP1425381B1 (en) Emu-based formulations for wound treatment related application information
EP0060553B1 (en) Preparation for treating outer skin wounds and process for manufacturing said preparation
CA3062005C (en) Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
AU655935B2 (en) Pharmaceutical composition of florfenicol
DE2736777A1 (en) SPRAYABLE Germicidal Foam Compositions
AU3963993A (en) Potentiation of antimicrobial effects
EP2030612A1 (en) Pharmaceutical composition for treating burns (variants) and a method for the production thereof (variants)
CN104586753A (en) Carboxymethyl chitosan antibacterial film spray and preparation method thereof
RU2140264C1 (en) Agent "polimed" for external use
WO2005049017A1 (en) Anti-inflammatory, regenerating and antimicrobial composition
EP0014238A2 (en) Mucilagenous synthetic lubricant and antifriction agent, especially for the vaginal region, and its use in diagnostic, surgical and treating medicine
RU2082399C1 (en) Composition for wound and burnt infections treatment
RU2408380C1 (en) Medicinal composition for treating joint diseases (versions)
RU2363487C2 (en) Compound possessing wound-healthing and antiinflammatory action
HK1045813A1 (en) Non-solid composition for local application comprising glycerol and alchemilla vulgaris extract
CN112704662B (en) Lidocaine emulsifiable paste, preparation method and application thereof
RU2381810C1 (en) Wound healing gel balm
RU2340328C1 (en) Agent possessing antimicrobic and antimicotic action
Ndlovu et al. Sodium alginate/carboxymethylcellulose gel formulations containing Capparis sepieria plant extract for wound healing
RU2221550C1 (en) Medicinal preparation for treatment of bacterial eczema, paraproctitis, burn, trophic ulcer and other sluggish wounds and method for preparing preparation
RU2737268C1 (en) Cosmetic and / or pharmaceutical composition for treating skin diseases
RU2316331C1 (en) Remedy for treating ultraviolet dermatitis cases, possessing anti-inflammatory and wound-healing activity
RU2682454C1 (en) Ointment for treatment of thermal burns and method for treatment thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase